

Appointment of Joint Company Secretary

Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) advises that Miss Alessandra Gauvin has been appointed as Joint Company Secretary alongside current Company Secretary, Mrs Eryn Dawson.

Ms Gauvin is an experienced corporate governance professional with over 6 years of company secretarial experience working with ASX listed companies across a diverse range of industries including mining, technology, biotech and industrials. Ms Gauvin is a Chartered Secretary and holds a Bachelor of Commerce and a Graduate Diploma in Applied Corporate Governance.

For the purposes of ASX Listing Rule 12.6, Ms Gauvin will be the person responsible for communications between the Company and ASX.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy

Executive Director

td@neurotechinternational.com

+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD, a Phase I/II trial in Rett Syndrome and completed a Phase I/II trial in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS. In addition, Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.